2. JAK/STAT Signaling Stem Cell/Wnt Apoptosis Epigenetics Protein Tyrosine Kinase/RTK
  3. STAT Apoptosis JAK
  4. AH057

AH057 is an orally active JAK1 and JAK2 inhibitor. AH057 blocks IL-6-, IFN-α- and IFN-γ-induced JAK/STAT signaling, reduces cancer cell proliferation, invasion and colony formation, and induces apoptosis and G1 cell-cycle arrest. AH057 can be used for cervical cancer research.

For research use only. We do not sell to patients.

AH057

AH057 Chemical Structure

CAS No. : 118499-11-9

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

AH057 Related Antibodies

Top Publications Citing Use of Products

View All STAT Isoform Specific Products:

View All Isoforms
STAT3 STAT5 STAT6 STAT1

View All JAK Isoform Specific Products:

View All Isoforms
JAK1 JAK2 JAK3 Tyk2 JAK

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

AH057 is an orally active JAK1 and JAK2 inhibitor. AH057 blocks IL-6-, IFN-α- and IFN-γ-induced JAK/STAT signaling, reduces cancer cell proliferation, invasion and colony formation, and induces apoptosis and G1 cell-cycle arrest. AH057 can be used for cervical cancer research[1].

IC50 & Target

JAK1

 

JAK2

 

STAT3

 

In Vitro

AH057 (1 μM; 2 h) selectively inhibits p-JAK2 (Tyr1007/1008) and p-STAT3 (Tyr705) without affecting p-AKT (Ser473) and p-p65 (Ser536) in HeLa cells[1].
AH057 (0.1-20 μM; 2 h) dose-dependently suppresses JAK2 and STAT3 phosphorylation in HeLa, DU145 and HepG2 cells; HeLa cervical cancer cells display the highest sensitivity[1].
AH057 (1 μM in HeLa cells, 10 μM in DU145 cells and 20 μM in HepG2 cells; 0.25-3 h) time-dependently inhibits JAK2 and STAT3 activation, and rapidly inhibits JAK2 phosphorylation within 15 min [1].
AH057 (1 h pretreatment; followed by IL-6 or IFN-α stimulation at 250 ng/mL for 1 h) blocks IL-6, IFN-α, IFN-γ induced phosphorylation of JAK1, JAK2, TYK2, STAT1 and STAT3 in HeLa, DU145 and HepG2 [1].
AH057 (1 h pretreatment; followed by IL-6 or IFN-α stimulation at 250 ng/mL for 4 h) downregulates IL-6-induced SOCS3 , and IFN-α-induced IRF1 and IRF2 mRNA expression in HeLa, DU145 and HepG2 cells[1].
AH057 (20 μM; 4 h) suppresses total tyrosine phosphorylation and STAT1/STAT3 activation in HEK293T cells overexpressing JAK1/JAK2/TYK2 JH1 kinase domain[1].
AH057 (0.0005-100 μM; 72 h) inhibits the viability of multiple cancer cell lines, and cervical cancer cell lines HeLa, CaSki and SiHa show IC50 values of 0.62 μM, 11.28 μM and 17.53 μM, respectively[1].
AH057 (0.2-100 μM; 48 h) impairs invasion capacity of HeLa, CaSki, SiHa cervical cancer cells, with no obvious inhibitory effect on HcerEpic normal cells[1].
AH057 (125-250 nM; 14 days) dose-dependently reduces colony formation number of cervical cancer cells[1].
AH057 (200 nM, 10 μM) inhibits wound healing migration of cervical cancer cells (Hela, CaSki) in vitro[1].
AH057 (0.5-20 μM; 24 h) triggers apoptotic cell death and induces G1/S cell cycle arrest in HeLa and CaSki cells; the proportion of G1 phase cells rises from 69.95% (DMSO) to 81.9% (1 μM AH057) in HeLa cells[1].
AH057 (500 nM + SGI-1027 (HY-13962) 1 μM; 24 h) combined with SGI-1027 produces synergistic apoptosis and stronger G1 phase arrest in HeLa cells, further downregulates Cyclin D1, Cyclin A2, Cyclin B1, Bcl-XL and Survivin, increases cleaved Caspase-3 and cleaved PARP, the combination therapy shows synergistic downregulation of certain genes (BAX, BCL-XL, BCL-2, MDM2, Cyclin A2, Cyclin D3, and CDK2). [1].
AH057 is identified by docking-based virtual screening as a JAK inhibitor candidate, and molecular docking shows that AH057 binds to the JAK2 active site pocket through hydrophobic interaction and hydrogen bonds with key residues including Tyr931 and Leu932[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

AH057 Related Antibodies

Western Blot Analysis[1]

Cell Line: HeLa
Concentration: 10 μM
Incubation Time: 4 h
Result: Showed the strongest inhibitory activity among nine top-ranking compounds against JAK2 phosphorylation and STAT3 phosphorylation.
Reduced pTyr1007/1008-JAK2 and pTyr705-STAT3 levels while maintaining total JAK2 and STAT3 protein levels.

Western Blot Analysis[1]

Cell Line: HeLa, DU145, HepG2
Concentration: HeLa (0.1, 0.5, 1.0, 1.5, 2.0 μM); DU145, HepG2 (1, 5, 10, 15, 20 μM)
Incubation Time: 2 h
Result: Reduced pTyr1007/1008-JAK2, pTyr705-STAT3 and pSer727-STAT3 levels in a dose-dependent manner.
HeLa cells showed higher AH057 sensitivity than DU145 and HepG2 cells.
Reduced JAK2 and STAT3 phosphorylation in both DU145 and HepG2 cells, confirming inhibition of JAK2/STAT3 signaling across multiple cancer cell lines.

Western Blot Analysis[1]

Cell Line: HeLa, DU145, HepG2
Concentration: 1 μM in HeLa cells; 10 μM in DU145 cells; 20 μM in HepG2 cells
Incubation Time: 0.25, 0.5, 1, 2, 3 h
Result: Time-dependently inhibited JAK2 and STAT3 activation.
Rapidly reduced JAK2 phosphorylation within 15 min, supporting direct inhibition of JAK2 kinase activity.

Western Blot Analysis[1]

Cell Line: HeLa, DU145, HepG2
Concentration: 1 μM in HeLa cells; 10 μM in DU145 cells; 20 μM in HepG2 cells
Incubation Time: 1 h pretreatment; IL-6, IFN-α or IFN-γ stimulation at 250 ng/mL for 1 h
Result: Blocked IL-6-induced JAK1, JAK2 and STAT3 phosphorylation.
Decreased IFN-α-induced JAK1, JAK2, TYK2, STAT1 and STAT3 phosphorylation.
Reduced IFN-γ-induced JAK1, JAK2, STAT1 and STAT3 phosphorylation.

Real Time qPCR[1]

Cell Line: HeLa, DU145, HepG2
Concentration: 1 μM in HeLa cells; 10 μM in DU145 cells; 20 μM in HepG2 cells
Incubation Time: 1 h pretreatment; IL-6, IFN-α or IFN-γ stimulation at 250 ng/mL for 4 h
Result: Suppressed IL-6-induced SOCS3 mRNA transcription and IFN-α-induced IRF1 mRNA transcription in all three cell lines.

Western Blot Analysis[1]

Cell Line: HEK293T cells overexpressing JAK1-JH1, JAK2-JH1 or TYK2-JH1
Concentration: 20 μM
Incubation Time: 4 h
Result: Reduced total tyrosine phosphorylation driven by overexpressed JAK1-JH1, JAK2-JH1 or TYK2-JH1.
Suppressed downstream STAT1 and STAT3 phosphorylation, supporting direct inhibition of JAK kinase domains.

Cell Viability Assay[1]

Cell Line: HcerEpic, HeLa, CaSki, SiHa, SK-OVR-3, ES-2, BT549, Huh7, Hep3B, HepG2, DU145, NCI-87, AGS, AsPC-3, U251
Concentration: 0.0005-100 μM
Incubation Time: 72 h
Result: Inhibited the viability of multiple cancer cell lines.
HeLa cells were the most sensitive tested cancer cells, with an IC50 of 0.62 μM.
CaSki and SiHa cervical cancer cells showed IC50 values of 11.28 μM and 17.53 μM, respectively.
Other cancer cell lines showed IC50 values ranging from 14.06 μM to 48.96 μM.

Cell Invasion Assay[1]

Cell Line: HcerEpic, HeLa, CaSki, SiHa
Concentration: 100 μM in HcerEpic cells; 200 nM in HeLa cells; 10 μM in CaSki and SiHa cells
Incubation Time: 48 h
Result: Impaired invasion ability of HeLa, CaSki and SiHa cervical cancer cells.
Did not significantly reduce invasion of normal HcerEpic cells under the tested condition.

Cell Proliferation Assay[1]

Cell Line: HcerEpic, HeLa, CaSki, SiHa
Concentration: 50, 100 μM in HcerEpic cells; 125, 250 nM in HeLa cells; 1, 5 μM in CaSki and SiHa cells
Incubation Time: 14 days
Result: Dose-dependently reduced colony formation in HeLa, CaSki and SiHa cervical cancer cells.
Did not significantly reduce colony formation of normal HcerEpic cells at 50 μM or 100 μM.

Cell Viability Assay[1]

Cell Line: HeLa
Concentration: 500 nM; 1 μM SGI-1027 (HY-13962)
Incubation Time: 48 h
Result: Synergistically reduced HeLa cell viability.
The combined effect of AH057 and SGI-1027 was time-dependent, and combination treatment induced stronger cell death than either single compound.

Apoptosis Analysis[1]

Cell Line: HeLa
Concentration: 500 nM; 1 μM SGI-1027 (HY-13962)
Incubation Time: 4 h
Result: Increased both early and late apoptotic cell populations.
Combination treatment induced a higher percentage of apoptotic cell death than either AH057 or SGI-1027 alone.

Western Blot Analysis[1]

Cell Line: HeLa
Concentration: 500 nM; 1 μM SGI-1027 (HY-13962)
Incubation Time: 24 h
Result: Enhanced cleaved PARP and cleaved caspase-3 levels.
Reduced the anti-apoptotic proteins Bcl-XL and Survivin, with stronger effects under combination treatment than either single compound.
Decreased Cyclin D1, Cyclin A2 and Cyclin B1 protein levels.
Combination treatment further potentiated the decrease in these cell-cycle regulators compared with AH057 alone.

Cell Cycle Analysis[1]

Cell Line: HeLa
Concentration: 500 nM; 1 μM SGI-1027 (HY-13962)
Incubation Time: 24 h
Result: Induced G1/S cell-cycle arrest. SGI-1027 alone increased S-phase accumulation, whereas combination treatment induced a higher G1-phase population than either single compound.
In Vivo

AH057 (50 mg/kg/day; p.o.; once daily; for 30 days ) suppresses tumor growth, induces tumor-cell apoptosis and reduces tumor-cell proliferation in HeLa xenograft BALB/c nude mouse model[1].
AH057 (50 mg/kg/day; p.o. ; for 24 days) combined with SGI-1027 (HY-13962; 50 mg/kg/day; p.o.) suppresses tumor growth in HeLa xenograft BALB/c nude mouse model, and the cardiac and renal toxicity of the compounds is inappreciable[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female 3-4 week-old BALB/c nude mice were subcutaneously injected with HeLa cells (1.5 × 106 cells/mouse) in the xenograft model [1]
Dosage: 50 mg/kg/day
Administration: Oral gavage (p.o.); once daily; for 30 days
Result: Significantly reduced HeLa xenograft tumor volume.
Was well tolerated with no mortality and no significant body weight loss during the trial.
Increased TUNEL-positive apoptotic cells in tumor tissues.
Reduced Ki67-positive tumor cells, indicating decreased tumor-cell proliferation.
Animal Model: Female 3–4 week-old BALB/c nude mice were subcutaneously inoculated with 1.5 × 106 HeLa cells per mouse to establish xenograft combination models and combined with 50 mg/kg/day SGI-1027[1]
Dosage: 50 mg/kg/day
Administration: Oral gavage (p.o.); once daily; for 24 days
Result: Suppressed HeLa xenograft tumor growth under oral administration.
Combination treatment showed stronger tumor-growth inhibition than vehicle treatment.
Cardiac and renal toxicity was inappreciable according to the accompanying toxicity data.
Molecular Weight

270.37

Formula

C17H22N2O
CAS No.
SMILES

OCC(CC)/N=C1C2=C(CCC/1)C3=C(C=CC(C)=C3)N2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

AH057 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

AH057118499-11-9AH 057AH-057STATApoptosisJAKJanus kinaseJAK1/2 inhibitorJAK2 inhibitorJAK/STAT signaling pathwaySTAT3STAT1TYK2IL-6IFN-αIFN-γSOCS3IRF1IRF2cervical cancerHeLaCaSkiSiHaHcerEpicDU145HepG2Huh7Hep3BES-2SK-OVR-3BT549NCI-87AGSAsPC-3U251cell viabilitycell invasioncolony formationapoptosisG1 cell cycle arrestTUNELKi67Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
AH057
Cat. No.:
HY-183519
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.